Tag: cron stock

Although near-term weakness exists in the cannabis stocks, we expect Cannabis 2.0 products or cannabis-derived products could act as a catalyst.

In September, Minnesota's state legislators conducted surveys to determine public sentiment about cannabis legalization. About 55% favored legalization.

For the last few months, there's been weakness in the cannabis sector. Investors were hoping for Canopy Growth and Aurora Cannabis to bring some relief.

After falling for the first two days this week, the cannabis sector maintained that weakness today. Let's look at some cannabis stocks that are in the news.

Today, Cronos Group (CRON) reported its third-quarter earnings, which ended on September 30. The company missed analysts’ revenue and EBITDA estimates.

This year, Aurora Cannabis (ACB) has lost 30.5% of its stock value as of Thursday. Should you start to consider buying the stock? Jim Cramer doesn't think so.

Aphria’s stock price has risen 8.9% since reporting its Q1 earnings on October 15. The cannabis sector's weakness offset some of these gains.

Curaleaf Holdings (CURA) (CURLF) had a great week. On October 30, GMP Securities analyst Robert Fagan restated the “Buy” rating.

The cannabis earnings season has started again. Earnings season is an exciting time for investors who have been eyeing the sector.

Yesterday, Canopy Growth (CGC) closed at 26.52 Canadian dollars, 1.49% lower than Tuesday's closing price. CGC is trading 5.27% higher than its 52-week low.